KLOW Blend — KPV, GHK-Cu, BPC-157 & TB-500 | Four-Peptide Regenerative Research Formulation
Research-Grade Compound
KLOW Blend is a four-peptide regenerative research formulation combining KPV (Lys-Pro-Val), GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), BPC-157 (Body Protection Compound-157, a 15-amino-acid gastric pentadecapeptide), and TB-500 (synthetic Thymosin β-4). The name is an acronym of its components — K for KPV, L for the lysine-containing copper tripeptide, O and W following the earlier GLOW naming convention.
In-depth research overview, mechanism of action, and study applications.
This Certificate of Analysis was issued by an independent third-party laboratory. Peptide.Express does not conduct in-house testing. Results are provided as-is from the testing facility and confirm batch identity, purity, and analytical methodology. For questions about specific CoA results, contact [email protected].
What is KLOW Blend?
KLOW Blend is a four-peptide regenerative research formulation combining KPV (Lys-Pro-Val), GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), BPC-157 (Body Protection Compound-157, a 15-amino-acid gastric pentadecapeptide), and TB-500 (synthetic Thymosin β-4). The name is an acronym of its components — K for KPV, L for the lysine-containing copper tripeptide, O and W following the earlier GLOW naming convention.
KLOW is the four-component evolution of the three-peptide GLOW stack (GHK-Cu, BPC-157, TB-500). The addition is KPV, the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone, which contributes NF-κB-directed anti-inflammatory activity and gut-barrier research relevance that the original three do not cover. Everything else in the formulation is unchanged.
The blend is studied in controlled in-vitro and preclinical settings for multi-pathway tissue repair, inflammation modulation, and extracellular matrix remodeling. Each component in the Peptide.Express blend is independently synthesized and HPLC-verified at ≥99% purity before compounding; the finished blend then undergoes compositional ratio verification. Standard vial size is 80 mg total blend mass.
How Does KLOW Blend Work? Mechanism of Action
The four peptides in KLOW do not share a pathway. That is the point of the formulation — each occupies a distinct mechanistic niche, and the research rationale for combining them rests on that separation rather than on any additive effect at a single target.
KPV (Lys-Pro-Val) — α-MSH-Derived Anti-Inflammatory Tripeptide
KPV is the C-terminal tripeptide (residues 11–13) of α-melanocyte-stimulating hormone. Molecular weight 342.4 Da. It suppresses pro-inflammatory cytokine production through interference with NF-κB nuclear translocation, and retains α-MSH's anti-inflammatory activity while lacking the melanocortin receptor agonism that drives pigmentation. In gut-barrier models, KPV is studied for effects on NF-κB-mediated inflammatory signaling and mucosal cytokine load.
KPV is the reason KLOW exists as a separate formulation from GLOW. Whether the tripeptide adds meaningfully to a blend that already contains two compounds with anti-inflammatory activity is an open question — no published study has tested the four-component combination directly.
GHK-Cu — Copper Delivery and Matrix Remodeling
GHK-Cu is a naturally occurring copper-binding tripeptide (C14H24CuN6O4, 403.9 Da) found in human plasma. It signals dermal fibroblasts to upregulate collagen synthesis, and simultaneously activates matrix metalloproteinases 1 and 2, which clear cross-linked and damaged collagen. The net effect studied in cell culture is tissue turnover rather than simple collagen accumulation.
The copper is not incidental. GHK-Cu is proposed to deliver bioavailable Cu²⁺ to lysyl oxidase, the copper-dependent enzyme that crosslinks collagen and elastin fibrils. Strip the copper out and much of the remodeling activity goes with it — this is why research protocols distinguish GHK from GHK-Cu.
BPC-157 — Local Angiogenesis and Mucosal Repair
BPC-157 (GEPPPGKPADDAGLV, C62H98N16O22, 1,419.5 Da) is a synthetic 15-amino-acid fragment of a protein sequence found in human gastric juice. Its most replicated preclinical mechanism is upregulation of VEGF expression, driving new blood vessel formation at the injury site. It also activates focal adhesion kinase and paxillin signaling, which accelerates fibroblast migration into wound beds and influences collagen fiber organization.
BPC-157 acts largely where it is placed. In rodent tendon and gastrointestinal injury models the effect is concentrated at the local site rather than distributed systemically.
TB-500 — Systemic Cell Migration via Actin Sequestration
TB-500 is synthetic Thymosin β-4, containing the LKKTET actin-binding motif. It regulates G-actin (monomeric) sequestration, modulating the G-actin to F-actin ratio that governs whether a cell can change shape and move. Freeing cells from actin-mediated immobility is what enables endothelial cells, keratinocytes and progenitor populations to migrate toward an injury site.
TB-500 is the systemic counterpart to BPC-157 in this blend. Where BPC-157 activates repair locally, TB-500 coordinates the recruitment of cells to that site from elsewhere. The two mechanisms operate on different cell populations and different timescales, which is the strongest available argument for studying them together.
Research Applications of KLOW Blend
Multi-Pathway Tissue Repair Models
- Tendon and ligament fibroblast studies: BPC-157 drives VEGF-mediated angiogenesis while TB-500 supplies the cell-migration signal, allowing researchers to separate vascular from cellular contributions to repair.
- Dermal wound-healing assays: GHK-Cu provides the collagen synthesis and MMP-mediated remodeling arm that the other three components do not address.
- Combination pharmacology design: the blend is used as a positive control when investigators want a maximal multi-pathway repair signal against which single-compound arms can be compared.
Inflammation and Barrier-Function Research
- NF-κB pathway readouts: KPV suppresses nuclear translocation of NF-κB, giving a distinct anti-inflammatory readout separate from GHK-Cu's antioxidant activity.
- Intestinal epithelial monolayer models: KPV and BPC-157 are both studied for mucosal inflammation and barrier-repair models, though through unrelated mechanisms.
- Cytokine profiling: pro-inflammatory cytokine panels are the standard endpoint when the blend is used in inflammation models.
Extracellular Matrix and Aging Models
- Fibroblast collagen expression: Type I and Type III collagen transcription is the primary GHK-Cu-driven endpoint.
- Copper-dependent enzyme activity: lysyl oxidase function provides a mechanistic link between copper delivery and matrix crosslinking.
- Oxidative stress assays: GHK-Cu scavenges reactive oxygen species and upregulates superoxide dismutase activity in cell models.
KLOW Blend vs GLOW Blend
| Feature | GLOW Blend | KLOW Blend |
|---|---|---|
| Components | GHK-Cu, BPC-157, TB-500 | KPV, GHK-Cu, BPC-157, TB-500 |
| Component count | 3 peptides | 4 peptides |
| Added compound | — | KPV (Lys-Pro-Val), 342.4 Da |
| Anti-inflammatory pathway | GHK-Cu (antioxidant, ROS scavenging) | GHK-Cu + KPV (NF-κB suppression) |
| Gut-barrier relevance | BPC-157 only | BPC-157 + KPV (cytokine/NF-κB models) |
| Collagen / matrix remodeling | GHK-Cu | GHK-Cu |
| Systemic cell migration | TB-500 | TB-500 |
| Local angiogenesis | BPC-157 (VEGF) | BPC-157 (VEGF) |
The only difference between the two formulations is KPV. Everything researchers value in GLOW is present in KLOW; the question worth asking is whether an additional α-MSH-derived anti-inflammatory tripeptide changes the readout in a given model, and that has not been formally tested.
Read the full KLOW vs GLOW peptide comparisonKLOW Blend Technical Specifications
| Compound Name | KLOW Blend (four-peptide research formulation) |
|---|---|
| Components | KPV (Lys-Pro-Val), GHK-Cu, BPC-157, TB-500 |
| Common Synonyms | KLOW, KLOW peptide, KLOW stack, K-LOW blend |
| KPV | Lys-Pro-Val, C16H30N4O4, 342.4 Da, CAS 67727-97-3 |
| GHK-Cu | Gly-His-Lys·Cu(II), C14H24CuN6O4, 403.9 Da, CAS 89030-95-5 |
| BPC-157 | GEPPPGKPADDAGLV, C62H98N16O22, 1,419.5 Da, CAS 137525-51-0 |
| TB-500 | Synthetic Thymosin β-4, 4,963.4 Da, CAS 77591-33-4 |
| Standard Vial Size | 80 mg total blend mass |
| Purity | ≥99% per component by HPLC |
| Purity Confirmation | LC-MS/MS molecular weight verification per component |
| Blend Verification | Compositional ratio verification post-blend |
| Endotoxin Testing | LAL (Limulus Amebocyte Lysate) method |
| Physical Form | Lyophilized powder blend |
| Appearance | Deep blue powder — the GHK-Cu component colours the whole blend |
| Reconstitution | Bacteriostatic water, 2–3 mL for a standard 80 mg vial |
| Storage (lyophilized) | -20°C, desiccated, protected from light |
| Storage (reconstituted) | 2–8°C, use within 14–28 days |
| Shelf Life | 24 months from manufacture (lyophilized) |
| Testing Methods | HPLC, LC-MS/MS, LAL Endotoxin |
| Documentation | Certificate of Analysis (CoA) per batch |
| Intended Use | In-vitro laboratory research only |
How to Reconstitute KLOW Blend for Research
The 80 mg vial is unusually large for a peptide blend, so the volume arithmetic matters more than it does for a 5 mg single-compound vial. At 2.5 mL of diluent the resulting solution is 32 mg/mL of total blend mass — a concentrated solution that dissolves more slowly than a dilute one. Give it the full 90 seconds.
- Allow the vial to reach room temperature before opening. Cold glass encourages condensation on the septum.
- Draw the calculated volume of bacteriostatic water. For a standard 80 mg vial, 2.5 mL yields 32 mg/mL total blend concentration; 3 mL yields approximately 26.7 mg/mL.
- Swab the vial septum with alcohol and allow 30 seconds to dry.
- Insert the needle at an angle and inject the diluent slowly against the inner vial wall — not directly onto the lyophilized cake. Spraying onto the powder causes foaming and can denature peptide.
- Swirl gently for 60–90 seconds. Do not shake and do not vortex.
- Inspect the solution. It should be clear and blue — the GHK-Cu component carries its colour into the reconstituted blend. Discard if cloudy, if particulate matter is visible, or if a precipitate forms.
- Label the vial with the reconstitution date and resulting concentration.
- Store at 2–8°C and use within 14–28 days. Avoid repeated freeze-thaw cycles.
Diluent: bacteriostatic water for peptide reconstitution. Full protocol: step-by-step peptide reconstitution guide. Concentration maths: peptide reconstitution calculator.
Frequently Asked Questions — KLOW Blend
What is KLOW Blend used for in research?
What is in KLOW Blend?
What does the KLOW peptide do?
What is the difference between GLOW and KLOW peptides?
What peptide does Jennifer Aniston use?
How long should KLOW be studied for in a research protocol?
How do I reconstitute an 80 mg KLOW vial?
What concentration should KLOW Blend be prepared at?
Is KLOW the same as the Wolverine Blend?
Can KLOW be studied alongside other peptides?
What purity standard does Peptide.Express use for KLOW Blend?
What testing does KLOW Blend undergo before shipping?
How should KLOW Blend be stored before and after reconstitution?
Where is the Certificate of Analysis for KLOW Blend?
Research References
- Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences, 2018. Read the GHK-Cu regenerative gene-data review on PMC
- Pickart L, Vasquez-Soltero JM, Margolina A. "The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging." Oxidative Medicine and Cellular Longevity, 2012. Read the GHK-Cu oxidative stress review on PMC
- Narrative review of BPC-157 for musculoskeletal healing, covering the VEGF and focal adhesion kinase mechanisms and the limits of the current evidence base. Biomolecules, 2025. Read the BPC-157 musculoskeletal healing review on PMC
- Goldstein AL, Hannappel E, Kleinman HK. "Thymosin Beta4: Actin-Sequestering Protein Moonlights to Repair Injured Tissues." Trends in Molecular Medicine, 2005. Read the thymosin β4 actin-sequestration and tissue-repair review on PubMed
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. "PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation." Gastroenterology, 2008. Read the KPV NF-κB and intestinal-inflammation study on PMC
All products are sold for in-vitro laboratory research use only. Not intended for human consumption, clinical use, or veterinary use. Peptide.Express makes no medical claims. Consult the published literature for research application guidance.